MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study

Laborértékek

• History of AF, AF on 12-lead ECG on admission or any AF ≥30 seconds during heart-rhythm monitoring prior to randomization; Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as per Investigator’s judgment including therapeutic dose of low-molecularweight heparin or heparin; Strong likelihood to be treated with prolonged (i.e. more than 90 days) dual antiplatelet therapy during the course of the trial (such as coronary stenting, etc.); Patients undergoing planned procedures where therapy with a DOAC is a contraindication (e.g. acute surgery); Previous intracranial symptomatic hemorrhage in the last 24 months; Evidence of severe cerebral amyloid angiopathy if MRI scan performed; Chronic kidney disease with creatinine clearance <30ml/min and or subject who requires haemodialysis or peritoneal dialysis; Known bleeding diathesis (e.g. active peptic ulcer disease, platelet count < 100’000/mm3 or haemoglobin < 8 g/dl or INR ≥ 1.7, documented haemorrhagic tendencies or blood dyscrasias); Active infective endocarditis; Known allergy or intolerance to antiplatelets or DOACs; Female who is pregnant or lactating or has a positive pregnancy test at time of admission; If restricted by national law: Current participation in another drug trial

• MR-proANP level ≥200pmol/L within 72 hours from symptom onset, Age ≥ 18 years, Clinical diagnosis of ischemic stroke, Written informed consent according to country specific details